{"podcast":{"title":"Breast Cancer Update","slug":"breast-cancer-update-757579","podcast_index_feed_id":757579,"rss_url":"https://feeds.captivate.fm/breast-oncology/","website_url":"https://www.researchtopractice.com/browse-by-tumor-types/breast-cancer","image_url":"https://artwork.captivate.fm/ad97e2be-455a-4b53-ab3d-383838c145e5/cbjJP3tyd5NWFP4W5DD1CnhC.png","author":"Dr. Neil Love","episode_count":118,"summary":"Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.","last_synced_at":"2026-09-22T02:17:02.774213+00:00","page_url":"https://stenobird.com/podcast/breast-cancer-update-757579"},"episode":{"title":"For Oncology Nurses: CDK4/6 Inhibitors for Breast Cancer — Proceedings from the 2026 Annual ONS Congress","slug":"for-oncology-nurses-cdk4-6-inhibitors-for-breast-cancer-proceedings-from-the-2026-annual-ons-congress","published_at":"2026-07-29T14:00:00+00:00","page_url":"https://stenobird.com/podcast/breast-cancer-update-757579/for-oncology-nurses-cdk4-6-inhibitors-for-breast-cancer-proceedings-from-the-2026-annual-ons-congress","show_page_url":"https://stenobird.com/podcast/breast-cancer-update-757579","url":"https://breast-oncology.captivate.fm/episode/6097-ons2026-cdk46bc","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/98a33e1e-109e-4da8-b2f6-3bc9094d410d.mp3","summary":"Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics: Introduction (00:00) Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24) Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52) Adjuvant CDK4/6 Inhibitor Therapy (17:14) Practical Considerations with CDK4/6 Inhibitors (29:57) Monitoring and Management of Cytopenias (42:02) CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32) Management of Gastrointestinal Adverse Events (1:03:47) CDK4/6 Inhibitors in Unique Populations (1:10:41) Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48) CME information and select publications","meta_description":"Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following…","key_points":[],"chapters":[],"topics":[],"duration_seconds":5348,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/breast-cancer-update-757579/episodes/for-oncology-nurses-cdk4-6-inhibitors-for-breast-cancer-proceedings-from-the-2026-annual-ons-congress/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/breast-cancer-update-757579/for-oncology-nurses-cdk4-6-inhibitors-for-breast-cancer-proceedings-from-the-2026-annual-ons-congress.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}